Agenda
18:30 (BST)
Gilles Salles
Welcome and introductions
- Introduction to the Lymphoma Hub
- Educational objectives and pre-symposium test
- Introduction to the speakers
18:35 (BST)
Gilles Salles
Unmet needs with BTKis in CLL
- Overview of the current treatment guidelines for BTKis
- Real-world experience with BTKis
- Live Q&A with the audience
18:50 (BST)
Paolo Ghia
BTKis: Current and future perspectives
- Overview of emerging BTKis for CLL
- Key efficacy and safety data from clinical trials
- Live Q&A with the audience
19:05 (BST)
Francesc Bosch
BTKis in clinical practice for CLL: Case study clinic
- Interactive case studies and panel discussion to review optimal treatment selection for CLL in patient subgroups, including high- versus low-risk patients, sequencing strategies, dosing flexibility, and the role of minimal residual disease
- Live Q&A with the audience
Learning objectives
Upon completion of this activity, participants should be able to:
- Describe novel therapeutic targets in CLL and explain the mechanisms of action for new agents.
- Recall the latest data for new agents, including their regulatory status in CLL, and describe the rationale for selecting such treatments based on previous treatments and patient-related factors.
- Describe the adverse event profiles of novel agents, and state how adverse events could be managed in clinical practice.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy